32 results about "Cyclohexylacetic acid" patented technology

A method of promoting activated, pleasant moods through the inhalation of energising, non-stressing fragrances (invigorating fragrances) comprising at least 75% by weight, preferably 85% by weight of perfume materials drawn from the following groups:

• A) At least 10% by weight in total of at least three materials drawn from Group ‘IMP’ comprising: allyl amyl glycolate; benzyl salicylate; bergamot oil; coriander oil; cyclamen aldehyde; 1-(2,6,10-trimethylcyclododeca-2,5,9-trien-1-yl)ethanone; allyl (cyclohexyloxy)acetate; Damascenia 185 SAE; 2,4-dimethylheptan-1-ol; fir balsam; fir needle oil; 3-(4-ethylphenyl)-2,2-dimethylpropanal; ginger oil; guaiacwood; linalyl acetate; litsea cubeba oil; methyl 2,4-dihydroxy-3,6-dimethylbenzoate; nutmeg oil; olibanum oil; orange flower oil; Ozonal AB 7203C; patchouli oil; rose oxide; rosemary oil; sage clary oil; spearmint oil; Tamarine AB 8212E; tarragon oil;
• B) Optionally up to 90% of materials from the following groups:
  • Group ‘HMR’ comprising:
  • allyl ionone; benzyl acetate; cis-jasmone; citronellol; ethyl linalol; ethylene brassylate; 4-methyl-2-(2-methylpropyl)tetrahydro-2H-pyran-4-ol; geraniol; geranium oil; isoeugenol; lemon oil; 2,4-dimethylcyclohex-3-ene-1-carbaldehyde; 3-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; 4-(4-hydroxy-4-methylpentyl)cyclohex-3-ene-1-carbaldehyde; alpha-iso-methyl ionone; 3-methylcyclopentadec-2-en-1-one; cyclopentadecanone; cyclohexadecanolide; gamma-undecalactone.
  • Group ‘HMI’ comprising:
  • 1-{[2-(1,1 -dimethylethyl)cyclohexyl]oxy}butan-2-ol; 3a,6,6,9a-tetramethyldodecahydronaphtho[2,1 -{b}]furan; alpha-damascone; dihydromyrcenol; eugenol; 3-(1,3-benzodioxol-5-yl)-2-methylpropanal; 2,4-dimethylcyclohex-3-ene-1-carbaldehyde; mandarin oil; orange oil; 2-(1,1-dimethylethyl)cyclohexyl acetate.
  • Group ‘HMP’ comprising:
  • 1-(2,6,6,8-tetramethyltricyclo[5.3.1.0 {1,5}]undec-8-en-9-yl)ethanone; allyl cyclohexyl propionate; allyl heptanoate; Apple Oliffac S pcmf; 7-methyl-2H-1,5-benzodioxepin-3(4H)-one; cassis base; cis-3-hexenyl salicylate; damascenone; gamma-decalactone; ethyl acetoacetate; ethyl maltol; ethyl methyl phenylglycidate; hexyl acetate; (3E)-4-methyldec-3-en-5-ol; 2,5,5-trimethyl-6,6-bis(methyloxy)hex-2-ene; 4-(4-hydroxyphenyl)butan-2-one; styrallyl acetate; 2,2,5-trimethyl-5-pentylcyclopentanone; ylang oil. Group ‘RMP’ comprising: anisic aldehyde; (2Z)-2-ethyl-4-(2,2,3-trimethylcyclopent-3-en-1-yl)but-2-en-1-ol; benzoin siam resinoid; ethyl vanillin; oxacyclohexadec-12(13)-en-2-one; hexyl salicylate; hydroxycitronellal; jasmin oil; 3-methyl-5-phenylpentan-1-ol; 2-(phenyloxy)ethyl 2-methylpropanoate; alpha-terpineol; vanillin;
  • Group ‘GEN’ comprising:
  • cyclopentadecanolide; oxacyclohexadecan-2-one; hexyl cinnamic aldehyde; ionone beta; isobornyl cyclohexanol; 1-(2,3,8,8-tetramethyl-1,2,3,4,5,6,7(8),8(8a)-octahydronaphthalen-2-yl)ethanone; 4-(1,1-dimethylethyl)phenyl]-2-methylpropanal; linalol; methyl dihydrojasmonate; 2-phenylethanol;
  • provided the following conditions are met:
  • (a) IMPs>=HMPs+HMRs
  • (b) IMPs+HMIs+GENs>=70%
  • (c) (IMP+HMI)/(IMP+HMI+RMP+HMR)>=0.7
  • (d) IMPs/(HMPs+RMPs+IMPs)>=0.5
  • (e) IMPs/[(HMPs+RMPs+IMPs)+(100−TOTAL)]>=0.3
  • wherein ‘IMPs’ indicates the sum of the percentages of materials within Group IMP, and similarly for the remaining groups, the symbol ‘>=’ indicates ‘at least equal to’, and ‘TOTAL’ is the sum of HMPs, HMRs, HMIs, IMPs, RMPs and GENs, provided also that low odour or no odour solvents are excluded from the calculation of these sums is provided which have an invigorating effect when inhaled by a subject.

The invention provides a preparation method for a trans 4-amino-cyclohexyl acetate derivative. The preparation method comprises the following steps that a formula (please see the description for the formula) is provided, wherein R is methyl or ethyl; a compound III is prepared from the raw materials of 4-amino cyclohexanone II and is subjected to hydrogenation reduction, a compound I crude product is obtained, acid is added, and salt is formed; and a compound I is prepared by adding alkali. According to the preparation method, 4-amino cyclohexanone not protected by amino is adopted as raw materials, witting reaction is conducted, and then through catalytic hydrogenation, the trans crude product of the preparation method is obtained. The crude product can be subjected to salifying crystallization so as to obtain the purer trans product, and the trans:syn ratio is 95-99.9:5-0.1. The product compound is high in purity and can be used for preparing cariprazine. Operation is simple, the raw materials are easy to obtain, industrial production is suitable, and large application value is achieved.

A process for synthesizing gabapentin hydrochloride includes such steps as Backmann rearrangement reaction of spiro [3,5]-2-nonanone ó¾ to obtain 2-aza-spiro [4,5]-3-decanone ó�, hydrolyzing, and recrystallizing. Its advantages are simple process, low poison of raw material and low cost.

The invention discloses a preparation method for buparvaquone. The method comprises taking tert-butylcyclohexyl acetic acid, sodium omadine and 1,4-naphthoquinone as initial raw materials, firstly reacting tert-butylcyclohexyl acetic acid with sodium omadine to generate tert-butylcyclohexyl acetic acid 2-thioxo-pyridin-1-yl ester, then reacting with 1,4-naphthoquinone for addition, so as to generate 2-[(4-tert-butylcyclohexyl)methyl]-3-(2-pyridinylsulfanyl)-1,4-naphthalenedione, then mixing the obtained 2-[(4-tert-butylcyclohexyl)methyl]-3-(2-pyridinylsulfanyl)-1,4-naphthalenedione, methanol, tripotassium phosphate trihydrate and water, performing heating hydrolysis, processing the solution and acidifying, and filtering to obtain a buparvaquone crude product, and then recrystallizing by utilizing isopropanol, so as to obtain a buparvaquone competitive product. The method is simple in operation, relatively low in cost, high in product yield and relatively suitable for industrialized production.

The invention discloses a Pantoea amidase, a gene, a vector, an engineering bacterium and an application thereof in preparation of 1-cyancyclohexylacetic acid through biological catalysis of 1-cyancyclohexylacetamide. The amino acid sequence of the amidase is represented by SEQ ID NO.1. A synthesis technology of 1-cyancyclohexylacetic acid through biological catalysis by using the amidase is reported in the invention for the first time, and the technology has the substantial advantages of small catalyst dosage (2g/L), high substrate concentration (100g/L), short reaction time (20min), and high product conversion rate reaching 100%.

The invention discloses a 4-nitrophenylacetic-acid-catalyzing hydrogenation preparing method for trans-4-amino-cyclohexylacetic acid and hydrochloride. Under the condition of a multiple-active-component supported catalyst prepared with the method, a hydrogenation reaction has the high activity and selectivity, operating is easy, the cost of the catalyst is low, and other reaction steps are not required; the technology is 4-nitrophenylacetic-acid heterogeneous catalysis and hydrogenation, the reaction condition is mild, the method is efficient, simple, easy to carry out, economical and free of pollution, the technology is simple, and large-scale industrial production is facilitated.

The invention discloses a method for preparing a DGAT-1 inhibitor intermediate. The method comprises the following steps: reacting trans-4-(4-halogeno phenyl)cyclohexanecarboxylic acid chloride with diazomethane, and generating trans-4-(4-halogeno phenyl)cyclohexyl diazo-ketone; and performing Wolff rearrangement on trans-4-(4-halogeno phenyl)cyclohexyl diazo-ketone, and generating trans-4-(4-halogeno phenyl)cyclohexyl acetic acid. According to the method disclosed by the invention, the reaction steps are reduced, and the raw material cost is reduced.

The present invention discloses a nitrilase mutant and application thereof. The mutant is obtained by mutating the amino acid at position 201 or replacing one or more amino acids at region 324-381 of the amino acid sequence shown in SEQ ID No. 2. In the present invention, by the protein molecular modification, thermostability of the purified nitrilase LNIT5 is increased by up to 4.5 folds; and by utilizing recombinant E. coli containing the nitrilase mutant to hydrolyze 1-cyanocyclohexylacetonitrile at a high temperature (45° C.), product tolerance is increased, activity of NIT5-L201F is increased by 20%, and the mutant NIT_LNIT5-AcN can completely hydrolyze 750 mM 1-cyanocyclohexylacetonitrile within 8 hours and achieve an doubled conversion rate. Therefore, the mutants obtained by the present invention have a good application prospect in efficiently catalyzing 1-cyanocyclohexylacetonitrile to synthesize gabapentin intermediate, 1-cyanocyclohexyl acetic acid. In the present invention, by protein molecular modification, thermal stability of pure nitrilase LNIT5 at 45° C. is increased up to 4.5 times, and while 1-cyanocyclohexylacetonitrile is hydrolyzed using recombinant Escherichia coli containing nitrilase mutant at high temperature(45° C.), the product yield is increased. Therefore, the mutants obtained in the present invention have a good application prospect in highly efficiently catalyzing 1-cyanocyclohexylacetonitrile to 1-cyanocyclohexyl acetic acid, the gabapentin intermediate.

The invention discloses a method for screening and replacing a pET commercial plasmid promoter. According to the method, heterologous expression of nitrilase is adjusted from the transcriptional level, the correct folding proportion of nitrilase is increased, soluble expression is increased, and inhibition of inclusion body accumulation on thallus growth is relieved; the promoter mutant strain is subjected to shake-flask induced expression, and the thallus concentration, the specific enzyme activity and the fermentation liquor specific enzyme activity are 1.4 times, 1.6 times and 5.5 times higher than those of commercial plasmids respectively; meanwhile, in the reaction of catalytically preparing the gabapentin intermediate 1-cyanocyclohexyl acetic acid; and the catalytic efficiency of the promoter mutant strain is improved by more than 100% compared with that of the original strain.

The invention relates to a bacillus capable of degrading naphthenic acids and application of the bacillus capable of degrading the naphthenic acids and particularly relates, separates and identifies abacillus CR1 (in a preservation number of CGMCC NO.7368) capable of biologically degrading five types of naphthenic acids in different chemical structures. The bacillus grows by taking trans-4-methyl-cyclohexanecarboxylic acid, cis-4-methyl-cyclohexanecarboxylic acid, trans-4-tert-butylcyclohexanecarboxylic acid, trans-4-pentyl-cyclohexanecarboxylic acid and dicyclohexyl acetic acid as a unique carbon source, and trans-4-methyl-cyclohexanecarboxylic acid degrading rate and trans-4-pentyl-cyclohexanecarboxylic acid degrading rate are 93.2% and 42.2% respectively, and the bacillus can be applied to biodegradation of naphthenic acids.

The invention discloses a synthesis method of 4-tert-butyl cyclohexyl acetic acid, which comprises the following steps: dissolving 4-tert-butyl phenylacetic acid in a solvent, adding a catalyst into the solvent, carrying out high-pressure catalytic hydrogenation reaction, after the reaction is finished, filtering out the catalyst from reaction liquid, desolventizing and concentrating, adding concentrated liquid into water to separate out solid, centrifuging, and drying to obtain the 4-tert-butyl cyclohexyl acetic acid. The refined 4-tert-butyl cyclohexyl acetic acid is obtained. According to the synthesis method provided by the invention, 4-tert-butylphenylacetic acid is adopted as a raw material, the raw material is cheap and easy to obtain, a target product can be obtained through a one-step catalytic hydrogenation reaction, the synthesis process is efficient and simple, the reaction steps are short, the production cost is relatively low, the product yield is high, the product purity is high, and ions harmful to subsequent coupling reaction are not contained; the method has obvious advantages on subsequent synthesis of buparvaquone. In the whole production process, reaction conditions are mild, safe and environment-friendly, equipment conditions are easy to meet, and industrial production is facilitated.

The invention discloses a method for preparing 3-carbonyl-bicyclo[2.2.2]octane-2-formate, 2-(4-alkoxycarbonyl cyclohexylidene)acetate is used as an initial raw material, catalytic hydrogenation and condensation are sequentially performed to obtain the 3-carbonyl-bicyclo[2.2.2]octane-2-formate, and X and Y are independently selected from alkyl or aryl. According to the method, the synthetic route is short, the reaction conditions are mild, and the total yield is greater than 80%; and the method has the advantages of accessible raw materials, lower production cost and low facility request, and is suitable for large-scale industrial production.

The present invention provides a polypeptide tag and its application in the synthesis of pharmaceutical chemicals, the recombinant nitrilase was obtained by connecting a polypeptide tag to the N-terminus of the amino acid sequence of the nitrilase; wherein amino acids at both ends of the polypeptide tag are uncharged glycine G, and the rest are a random combination of any one or more of glycine G, histidine H, glutamic acid E, aspartic acid D, lysine K and arginine R; The activity of the recombinant nitrilase in the preparation of 1-cyanocyclohexyl acetic acid is up to 3034.7 U/g dcw, the polypeptide tag significantly improves the soluble expression of nitrilase, and the whole cell catalyst hydrolyzes 1M substrate with the same concentration 30 minutes faster than the mother enzyme. The method provided by the present invention can also be used for the biocatalytic reaction of other pharmaceutical intermediates as the substrate catalyzed by the nitrilase, improving the activity of the whole cell catalyst in reaction, and also improving the solubility of other types of nitrilases and the activity of the corresponding whole cell catalysts.